galidesivir bcx immucillina antivir drug adenosin analog type nucleosid analog develop biocryst pharmaceut fund niaid origin intend treatment hepat subsequ develop potenti treatment dead filovirus infect ebola virus diseas marburg virus diseas zika virus current galidesivir phase human trial brazil coronavirus also show broadspectrum antivir effect rang rna virus famili includ bunyavirus arenavirus paramyxovirus coronavirus flavivirus phlebovirus galidesivir demonstr protect ebola marburg virus rodent monkey even administ hour infect develop use human fasttrack due concern lack treatment option ebola virus epidem west africa galidesivir later show efficaci zika virus mous model galidesivir abrog viremia zika virusinfect rhesus macaqu galidesivir one sever antivir drug test coronavirus diseas april th biocryst open enrol random doubleblind placebocontroll clinic trial assess safeti clinic impact antivir effect galidesivir patient covid